Aspirin therapy demonstrated substantial value in improving survival and other major clinical outcomes in patients with suspected acute myocardial infarction.
Do aspirin, heparin, and fibrinolytic therapy improve survival and other major clinical outcomes in patients with suspected acute myocardial infarction?
This review summarizes the foundational evidence from randomized clinical trials regarding the survival benefits of aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction.
In this article, we review the randomized clinical trials of aspirin, of heparin, and of fibrinolytic therapy in patients with suspected acute myocardial infarction to determine which of these treatments have been shown to improve survival and other major clinical outcomes.AspirinBenefits of Aspirin during and after Suspected Myocardial InfarctionThe Second International Study of Infarct Survival (ISIS-2) demonstrated conclusively the substantial value of aspirin therapy in patients with suspected acute myocardial infarction1 (and other studies have shown the value of aspirin in patients with unstable angina2). In the ISIS-2 trial, assignment to one month of treatment with . . .
Collins et al. (Thu,) conducted a review in Suspected acute myocardial infarction. Aspirin, heparin, and fibrinolytic therapy was evaluated on Survival and other major clinical outcomes. Aspirin therapy demonstrated substantial value in improving survival and other major clinical outcomes in patients with suspected acute myocardial infarction.